skip to content
Pharmacoeconomic review report. Dolutegravir (Tivicay). Preview this item
ClosePreview this item
Checking...

Pharmacoeconomic review report. Dolutegravir (Tivicay).

Author: Canadian Agency for Drugs and Technologies in Health,
Publisher: Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, August 2014.
Series: Common drug review clinical review report.
Edition/Format:   eBook : Document : English
Summary:
Dolutegravir (Tivicay) (DTG) is being reviewed as a treatment of HIV in both treatment-naive and treatment-experienced adults and children 12 years of age and older and weighing at least 40 kg, in combination with other antiretrovirals. The recommended oral dose of DTG is 50 mg daily at a daily cost of $18.50.
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

Find a copy online

Links to this item

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Material Type: Document, Internet resource
Document Type: Internet Resource, Computer File
All Authors / Contributors: Canadian Agency for Drugs and Technologies in Health,
OCLC Number: 1086616835
Notes: "Manufacturer, ViiV Healthcare ULC."
Description: 1 online resource (1 PDF file (vi, 20 pages)) : illustrations.
Series Title: Common drug review clinical review report.
Other Titles: Dolutegravir (Tivicay)
CDR pharmacoeconomic review report for Tivicay

Abstract:

Dolutegravir (Tivicay) (DTG) is being reviewed as a treatment of HIV in both treatment-naive and treatment-experienced adults and children 12 years of age and older and weighing at least 40 kg, in combination with other antiretrovirals. The recommended oral dose of DTG is 50 mg daily at a daily cost of $18.50.

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


Primary Entity

<http://www.worldcat.org/oclc/1086616835> # Pharmacoeconomic review report. Dolutegravir (Tivicay).
    a schema:Book, schema:MediaObject, schema:CreativeWork ;
    library:oclcnum "1086616835" ;
    library:placeOfPublication <http://id.loc.gov/vocabulary/countries/onc> ;
    schema:about <http://experiment.worldcat.org/entity/work/data/8938403243#Topic/antiretroviral_therapy_highly_active_economics> ; # Antiretroviral Therapy, Highly Active--economics
    schema:about <http://experiment.worldcat.org/entity/work/data/8938403243#Topic/cost_benefit_analysis> ; # Cost-Benefit Analysis
    schema:about <http://experiment.worldcat.org/entity/work/data/8938403243#Topic/heterocyclic_compounds_3_ring_economics> ; # Heterocyclic Compounds, 3-Ring--economics
    schema:about <http://experiment.worldcat.org/entity/work/data/8938403243#Place/canada> ; # Canada.
    schema:about <http://experiment.worldcat.org/entity/work/data/8938403243#Topic/heterocyclic_compounds_3_ring_administration_&_dosage> ; # Heterocyclic Compounds, 3-Ring--administration & dosage
    schema:about <http://experiment.worldcat.org/entity/work/data/8938403243#Topic/hiv_integrase_inhibitors_economics> ; # HIV Integrase Inhibitors--economics
    schema:about <http://experiment.worldcat.org/entity/work/data/8938403243#Topic/hiv_infections_drug_therapy> ; # HIV Infections--drug therapy
    schema:alternateName "Dolutegravir (Tivicay)" ;
    schema:alternateName "CDR pharmacoeconomic review report for Tivicay" ;
    schema:bookFormat schema:EBook ;
    schema:contributor <http://experiment.worldcat.org/entity/work/data/8938403243#Organization/canadian_agency_for_drugs_and_technologies_in_health> ; # Canadian Agency for Drugs and Technologies in Health,
    schema:datePublished "2014" ;
    schema:description "Dolutegravir (Tivicay) (DTG) is being reviewed as a treatment of HIV in both treatment-naive and treatment-experienced adults and children 12 years of age and older and weighing at least 40 kg, in combination with other antiretrovirals. The recommended oral dose of DTG is 50 mg daily at a daily cost of $18.50."@en ;
    schema:exampleOfWork <http://worldcat.org/entity/work/id/8938403243> ;
    schema:inLanguage "en" ;
    schema:isPartOf <http://experiment.worldcat.org/entity/work/data/8938403243#Series/common_drug_review_clinical_review_report> ; # Common drug review clinical review report.
    schema:isPartOf <http://experiment.worldcat.org/entity/work/data/8938403243#Series/cadth_common_drug_review> ; # CADTH common drug review
    schema:name "Pharmacoeconomic review report. Dolutegravir (Tivicay)."@en ;
    schema:productID "1086616835" ;
    schema:url <http://www.ncbi.nlm.nih.gov/books/NBK534163/> ;
    wdrs:describedby <http://www.worldcat.org/title/-/oclc/1086616835> ;
    .


Related Entities

<http://experiment.worldcat.org/entity/work/data/8938403243#Organization/canadian_agency_for_drugs_and_technologies_in_health> # Canadian Agency for Drugs and Technologies in Health,
    a schema:Organization ;
    schema:name "Canadian Agency for Drugs and Technologies in Health," ;
    .

<http://experiment.worldcat.org/entity/work/data/8938403243#Series/cadth_common_drug_review> # CADTH common drug review
    a bgn:PublicationSeries ;
    schema:hasPart <http://www.worldcat.org/oclc/1086616835> ; # Pharmacoeconomic review report. Dolutegravir (Tivicay).
    schema:name "CADTH common drug review" ;
    .

<http://experiment.worldcat.org/entity/work/data/8938403243#Series/common_drug_review_clinical_review_report> # Common drug review clinical review report.
    a bgn:PublicationSeries ;
    schema:hasPart <http://www.worldcat.org/oclc/1086616835> ; # Pharmacoeconomic review report. Dolutegravir (Tivicay).
    schema:name "Common drug review clinical review report." ;
    .

<http://experiment.worldcat.org/entity/work/data/8938403243#Topic/antiretroviral_therapy_highly_active_economics> # Antiretroviral Therapy, Highly Active--economics
    a schema:Intangible ;
    schema:name "Antiretroviral Therapy, Highly Active--economics"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/8938403243#Topic/cost_benefit_analysis> # Cost-Benefit Analysis
    a schema:Intangible ;
    schema:name "Cost-Benefit Analysis"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/8938403243#Topic/heterocyclic_compounds_3_ring_administration_&_dosage> # Heterocyclic Compounds, 3-Ring--administration & dosage
    a schema:Intangible ;
    schema:name "Heterocyclic Compounds, 3-Ring--administration & dosage"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/8938403243#Topic/heterocyclic_compounds_3_ring_economics> # Heterocyclic Compounds, 3-Ring--economics
    a schema:Intangible ;
    schema:name "Heterocyclic Compounds, 3-Ring--economics"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/8938403243#Topic/hiv_infections_drug_therapy> # HIV Infections--drug therapy
    a schema:Intangible ;
    schema:name "HIV Infections--drug therapy"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/8938403243#Topic/hiv_integrase_inhibitors_economics> # HIV Integrase Inhibitors--economics
    a schema:Intangible ;
    schema:name "HIV Integrase Inhibitors--economics"@en ;
    .


Content-negotiable representations

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.